CUSIP: 29970R105
Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / ADS
-
Total 13F shares
-
161,337
-
Share change
-
-96,865
-
Total reported value
-
$209,754
-
Put/Call ratio
-
0%
-
Price per share
-
$1.30
-
Number of holders
-
9
-
Value change
-
-$118,299
-
Number of buys
-
2
-
Number of sells
-
8
Quarterly Holders Quick Answers
What is CUSIP 29970R105?
CUSIP 29970R105 identifies EVAX - EVAXION BIOTECH A S - ADS in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2023
-
Previous quarter:
Q1 2023
Recent filing periods for CUSIP 29970R105:
Institutional Holders of EVAXION BIOTECH A S - ADS (EVAX) as of Q2 2023
As of 30 Jun 2023,
EVAXION BIOTECH A S - ADS (EVAX) was held by
9 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
161,337 shares.
The largest 9 holders included
SUSQUEHANNA INTERNATIONAL GROUP, LLP, Moloney Securities Asset Management, LLC, JPMORGAN CHASE & CO, Beacon Capital Management, LLC, MORGAN STANLEY, GROUP ONE TRADING, L.P., RHUMBLINE ADVISERS, SIMPLEX TRADING, LLC, and UBS Group AG.
This page lists
9
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.